![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Chelariu-Raicu, Anca; Nick, Alpa; Urban, Renata; Gordinier, Mary; Leuschner, Carola; Bavisotto, Linda; Dal Molin, Graziela Zibetti; Whisnant, John K. und Coleman, Robert L.
(2021):
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
In: Gynecologic Oncology, Bd. 160, Nr. 2: S. 418-426
Westin, Shannon N.; Labrie, Marilyne; Litton, Jennifer K.; Blucher, Aurora; Fang, Yong; Vellano, Christopher P.; Marszalek, Joseph R.; Feng, Ningping; Ma, XiaoYan; Creason, Allison; Fellman, Bryan; Yuan, Ying; Lee, Sanghoon; Kim, Tae-Beom; Liu, Jinsong; Chelariu-Raicu, Anca; Chen, Tsun Hsuan; Kabil, Nashwa; Soliman, Pamela T.; Frumovitz, Michael; Schmeler, Katheleen M.; Jazaeri, Amir; Lu, Karen H.; Murthy, Rashmi; Meyer, Larissa A.; Sun, Charlotte C.; Sood, Anil K.; Coleman, Robert L. und Mills, Gordon B.
(2021):
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.
In: Clinical Cancer Research, Bd. 27, Nr. 23: S. 6354-6365
Kim, Mark Seungwook; Ma, Shaolin; Chelariu-Raicu, Anca; Leuschner, Carola; Alila, Hector W.; Lee, Sanghoon; Coleman, Robert L. und Sood, Anil K.
(2020):
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.
In: Molecular Cancer Therapeutics, Bd. 19, Nr. 11: S. 2396-2406